Carregant...
Fitxers
Tipus de document
TesiVersió
Versió publicadaData de publicació
Tots els drets reservats
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/48641
Backbone N-modified peptides: beyond N-methylation
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
[cat]En química medicinal, la N-metilació de l’esquelet peptídic s’ha utilitzat àmpliament per a imposar restriccions conformacionals en pèptids i així optimitzar la seva activitat i selectivitat. D’altra banda, la introducció de grups N-Me en pèptids d’interès terapèutic també és una estratègia per a millorar la seva biodisponibilitat, ja que els pèptids N-metilats són més hidrofòbics, més resistents al trencament proteolític, i -en general- més permeables a través de les membranes biològiques. No obstant, s’han descrit molts pocs exemples en els quals s’hagi modificat l’esquelet peptídic amb d’altres grups N-alquil. Això es pot atribuir a la dificultat d’acilar residus N-alquilats amb grups més grans que N-Me, degut al major impediment estèric. L’objectiu principal de la present tesi ha estat explorar la viabilitat sintètica d’introduir nous N-substituents en pèptids, i comparar les propietats d’aquests nous pèptids N-substituïts amb les dels seus homòlegs N-metilats. En aquesta tesi demostrem que els pèptids modificats amb una cadena de N-trietilenglicol (N-TEG) es poden preparar amb mètodes ja establerts per a la síntesi de pèptids N-metilats. En incrementar la llargada de la cadena de N-oligoetilenglicol (N-OEG), l’acoblament sobre el residu N-alquilat no és viable en fase sòlida, però es pot aconseguir solució utilitzant un clorur d’àcid. Per a dos ciclopèptids model, vam sintetitzar diversos N-OEG anàlegs, i vam trobar que la introducció del grup N-OEG augmenta la hidrofobicitat de forma proporcional a la llargada de la cadena. També vam trobar que el reemplaçament del grup N-Me present en aquests pèptids per una cadena curta de N-OEG provoca una mínima pertorbació de la seva conformació i activitat biològica. En base aquesta observació, vam estudiar el grup N-(4-azidobutil) com a linker per a permetre la conjugació en pèptids que no poseeixen grups funcionals derivatitzables. Demostrem que el grup N-(4-azidobutil) es pot introduir en un pèptid utilitzant mètodes estàndard de síntesi en fase sòlida, i que la substitució d’un grup N-Me present en un pèptid pel nostre linker no altera la conformació del pèptid. També demostrem que grup N-(4-azidobutil) permet la conjugació mitjançant diverses transformacions químiques. Es tracta d’un linker ortogonal a la majoria de grups protectors emprats en síntesi de pèptids, i químicament inert a una gran varietat de grups funcionals. En conclusió, la modificació de l’esquelet peptídic amb d’altres N-substituents més grans que N-Me és factible, però sorgeixen dificultats sintètiques en incrementar el tamany del grup N-alquil. Considerant que el grup N-Me es troba present en nombrosos pèptids biològicament actius, la seva substitució per d’altres entitats químiques és una alternativa viable per a introduir diversitat estructural o alterar propietats farmacològiques importants quan no és possible o no interessa modificar d’altres posicions d’un pèptid.
[eng] Backbone N-methylation is becoming an increasingly important tool in peptide drug design, and has been widely used to optimize the activity and selectivity of peptide ligands as a result of conformational modulation. However, no systematic research has been conducted on modifying the peptide backbone with other N-alkyl substituents. The present doctoral thesis is aimed at introducing novel N-substituents into peptides, and comparing the conformational and biological properties of the resulting N-substituted peptides with those of their N-Me homologues. In a first project, we studied the effect of replacing backbone N-Me groups by an N-triethylene glycol (N-TEG) chain on hydrophobicity and conformation. For that, we chose Sansalvamide A peptide as a model, and we incorporated N-Me and N-TEG amino acids at the different positions of its cyclopentapeptide structure. We found that Fmoc-protected amino acids bearing the N-TEG group [i.e. N-CH2CH2(OCH2CH2)2OCH3] can be easily prepared in solution, and they are straightforward to incorporate into a resin-bound peptide. The acylation of N-TEG amines can be achieved in solid-phase by activating the following amino acid with triphosgene. In this way, N-TEG peptides are accessible by the same synthetic repertoire as that already established for N-Me peptides. Comparison of NMR data of our N-TEG vs. N-Me analogs gives evidence of similar conformational preferences for those peptides with the same N-alkylation pattern. Furthermore, comparison of their chromatographic retention parameters indicates that the incorporation of an N-TEG chain into a peptide provides a higher hydrophobicity than an N-Me group. In a second study, we chose Cilengitide as model peptide, and we replaced its backbone N-Me group by various N-oligoethylene glycol (N-OEG) chains of increasing size: namely N-OEG2, N-OEG11, and N-OEG23, which are respectively composed of 2, 11 and 23 ethylene oxide monomer units. The N-OEG2 cyclopeptide analog was straightforward to synthesize in solid-phase, using the same methodology as for the N-TEG analogs of Sansalvamide A peptide. The syntheses of the N-OEG11 and N-OEG23 cyclopeptides are hampered due to the increased steric hindrance exerted by the N-substituent, and could only be achieved by segment coupling, which takes place with epimerization and thus requires extensive product purification. The different N-OEG cyclopeptide analogs and the parent peptide were compared with respect to biological activity and lipophilicity. The N-OEG2 analog displayed the same capacity as Cilengitide to inhibit integrin-mediated adhesion of HUVEC and DAOY cells to their ligands vitronectin and fibrinogen. The N-OEG11 and N-OEG23 analogs also inhibited cell adhesion, though with less potency. Thus, replacement of the backbone N-Me group of Cilengitide by a short N-OEG chain provides a more lipophilic analog with a similar biological activity. Upon increasing the size of the N-OEG chain, lipophilicity is enhanced, but synthetic yields drop and the longer polymer chains may impede receptor binding. On the basis of our finding that N-alkyl chains exert similar conformational constraints as a backbone N-Me group when incorporated into a cyclic peptide, we studied the N-(4-azidobutyl) group as a linker to permit conjugation in peptides that lack derivatizable groups (i.e. N-terminus, C-terminus, and side-chain functionalities). We developed a robust strategy for the introduction of this linker into a peptide using standard solid-phase peptide synthesis techniques. With this methodology, we synthesized an analog of Cilengitide in which its backbone N-Me group was replaced by the N-(4-azidobutyl) group. This N-(4-azidobutylated) analog was used to prepare several conjugates with a polydisperse PEG chain (2 KDa), showing that our linker allows conjugation either via click chemistry or -after azide reduction- via acylation or reductive alkylation. This linker is orthogonal to protecting groups and resins commonly used in peptide chemistry, and chemically inert to a wide range of functionalities. NMR data indicated that Cilengitide and its N-(4-azidobutylated) analog have the same backbone conformation. Therefore, substitution of a backbone N-Me group by the N-(4-azidobutyl) linker is a valuable strategy to provide a reactive site for the attachment of molecules whilst preserving the original peptide sequence and conformation. In summary, we have found that peptides bearing larger N-substituents than an N-Me group can be easily synthesized, but difficulties arise upon increasing the size of N-alkyl group. For Sansalvamide A peptide and Cilengitide, replacement of a backbone N-Me group by a short N-OEG chain resulted in analogs with similar biological activity and conformational features. This concept was then employed for the design of the N-(4-azidobutyl) linker, which allows bioorthogonal conjugation of a desired molecule with minimal perturbation of a target peptide structure. Considering the high abundance of N-Me groups in biologically active peptides, we contend that modification at this position is a feasible alternative to introduce chemical diversity or alter pharmacologically important parameters when modification at any other position of the peptide is not wished or possible.
[eng] Backbone N-methylation is becoming an increasingly important tool in peptide drug design, and has been widely used to optimize the activity and selectivity of peptide ligands as a result of conformational modulation. However, no systematic research has been conducted on modifying the peptide backbone with other N-alkyl substituents. The present doctoral thesis is aimed at introducing novel N-substituents into peptides, and comparing the conformational and biological properties of the resulting N-substituted peptides with those of their N-Me homologues. In a first project, we studied the effect of replacing backbone N-Me groups by an N-triethylene glycol (N-TEG) chain on hydrophobicity and conformation. For that, we chose Sansalvamide A peptide as a model, and we incorporated N-Me and N-TEG amino acids at the different positions of its cyclopentapeptide structure. We found that Fmoc-protected amino acids bearing the N-TEG group [i.e. N-CH2CH2(OCH2CH2)2OCH3] can be easily prepared in solution, and they are straightforward to incorporate into a resin-bound peptide. The acylation of N-TEG amines can be achieved in solid-phase by activating the following amino acid with triphosgene. In this way, N-TEG peptides are accessible by the same synthetic repertoire as that already established for N-Me peptides. Comparison of NMR data of our N-TEG vs. N-Me analogs gives evidence of similar conformational preferences for those peptides with the same N-alkylation pattern. Furthermore, comparison of their chromatographic retention parameters indicates that the incorporation of an N-TEG chain into a peptide provides a higher hydrophobicity than an N-Me group. In a second study, we chose Cilengitide as model peptide, and we replaced its backbone N-Me group by various N-oligoethylene glycol (N-OEG) chains of increasing size: namely N-OEG2, N-OEG11, and N-OEG23, which are respectively composed of 2, 11 and 23 ethylene oxide monomer units. The N-OEG2 cyclopeptide analog was straightforward to synthesize in solid-phase, using the same methodology as for the N-TEG analogs of Sansalvamide A peptide. The syntheses of the N-OEG11 and N-OEG23 cyclopeptides are hampered due to the increased steric hindrance exerted by the N-substituent, and could only be achieved by segment coupling, which takes place with epimerization and thus requires extensive product purification. The different N-OEG cyclopeptide analogs and the parent peptide were compared with respect to biological activity and lipophilicity. The N-OEG2 analog displayed the same capacity as Cilengitide to inhibit integrin-mediated adhesion of HUVEC and DAOY cells to their ligands vitronectin and fibrinogen. The N-OEG11 and N-OEG23 analogs also inhibited cell adhesion, though with less potency. Thus, replacement of the backbone N-Me group of Cilengitide by a short N-OEG chain provides a more lipophilic analog with a similar biological activity. Upon increasing the size of the N-OEG chain, lipophilicity is enhanced, but synthetic yields drop and the longer polymer chains may impede receptor binding. On the basis of our finding that N-alkyl chains exert similar conformational constraints as a backbone N-Me group when incorporated into a cyclic peptide, we studied the N-(4-azidobutyl) group as a linker to permit conjugation in peptides that lack derivatizable groups (i.e. N-terminus, C-terminus, and side-chain functionalities). We developed a robust strategy for the introduction of this linker into a peptide using standard solid-phase peptide synthesis techniques. With this methodology, we synthesized an analog of Cilengitide in which its backbone N-Me group was replaced by the N-(4-azidobutyl) group. This N-(4-azidobutylated) analog was used to prepare several conjugates with a polydisperse PEG chain (2 KDa), showing that our linker allows conjugation either via click chemistry or -after azide reduction- via acylation or reductive alkylation. This linker is orthogonal to protecting groups and resins commonly used in peptide chemistry, and chemically inert to a wide range of functionalities. NMR data indicated that Cilengitide and its N-(4-azidobutylated) analog have the same backbone conformation. Therefore, substitution of a backbone N-Me group by the N-(4-azidobutyl) linker is a valuable strategy to provide a reactive site for the attachment of molecules whilst preserving the original peptide sequence and conformation. In summary, we have found that peptides bearing larger N-substituents than an N-Me group can be easily synthesized, but difficulties arise upon increasing the size of N-alkyl group. For Sansalvamide A peptide and Cilengitide, replacement of a backbone N-Me group by a short N-OEG chain resulted in analogs with similar biological activity and conformational features. This concept was then employed for the design of the N-(4-azidobutyl) linker, which allows bioorthogonal conjugation of a desired molecule with minimal perturbation of a target peptide structure. Considering the high abundance of N-Me groups in biologically active peptides, we contend that modification at this position is a feasible alternative to introduce chemical diversity or alter pharmacologically important parameters when modification at any other position of the peptide is not wished or possible.
Matèries
Matèries (anglès)
Citació
Col·leccions
Citació
FERNÁNDEZ-LLAMAZARES ONRUBIA, Ana iris. Backbone N-modified peptides: beyond N-methylation. [consulta: 24 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/48641]